BioAtla, Inc. (NASDAQ:BCAB) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET

Company Participants

Bruce Mackle - Investor Relations, LifeSci Advisors, LLC
Jay Short - Chairman, Chief Executive Officer and Cofounder
Richard Waldron - Chief Financial Officer
Eric Sievers - Chief Medical Officer

Conference Call Participants

Brian Cheng - JPMorgan
Kaveri Pohlman - BTIG
Dev Prasad - Jefferies
Arthur He - H.C. Wainwright

Operator

Good afternoon, ladies and gentlemen, and welcome to the BioAtla Third Quarter 2023 Earnings Call. At this time, all lines are in a listen-only mode. Following the presentation, we will conduct a question-and-answer session. [Operator Instructions] Please be advised that this call is being recorded on Tuesday, November 7, 2023.

I would now like to turn the conference over to Bruce Waldron of LifeSci Advisors. Please go ahead.

Bruce Mackle

Thank you, operator, and good afternoon, everyone. With me today on the phone from BioAtla are Dr. Jay Short, Chairman, CEO and Co-Founder; and Rick Waldron, Chief Financial Officer.

Following today's call, Dr. Eric Sievers, Chief Medical Officer; and Sheri Lydick, Chief Commercial Officer, will join Jay and Rick for a short Q&A. Earlier this afternoon, BioAtla released financial results and a business update for the third quarter ended September 30th, 2023. A copy of the press release and corporate presentation are available on the company's website.

Before we begin, I'd like to remind everyone that statements made during this conference call will include forward-looking statements, including, but not limited to, statements regarding BioAtla's business plans and prospects and whether it's clinical trials will support registration, plans to form collaborations and other strategic partnerships for selected assets; results, conduct, progress and timing of its research and development programs in clinical trials; expectations with respect to enrollment and dosing in its clinical trials, plans and expectations regarding future data updates, clinical trials, regulatory meetings and regulatory submissions. The potential regulatory approval path for its product candidates; expectations about the sufficiency of its cash and cash equivalents, plans to prioritize and focus development on selected assets and indications and expected R&D and G&A expenses.

These statements are subject to various risks, assumptions and uncertainties that can cause actual results to differ materially and are described in the filings made with the SEC, including the most recent quarterly report on Form 10-Q.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today, November 7, 2023, and BioAtla disclaims any obligation to update such statements to reflect future information, events or circumstances, except as required by law.